Groopman, Jerome
August 1996
New Republic;8/12/96, Vol. 215 Issue 7, p14
Discusses the possible factors that may amount to a cure of AIDS as presented at the AIDS Conference in Vancouver, British Columbia in August 1996. Drugs that slow the rate at which the human immune deficiency virus replicates; Factors that could improve the health of AIDS patients; Areas of the body where the virus reproduces; List of strategic aims that are based on the success and limitations of triple drug therapy.


Related Articles

  • Living With The Enemy: Never Letting Our Guard Down. Murray, Jeffrey S. // FDA Consumer;Nov/Dec2001, Vol. 35 Issue 6, p40 

    Comments on the treatment of HIV and AIDS. Difference of the treatment of HIV with other chronic illnesses; First step in dealing with HIV battle fatigue; Characteristics of drugs that are in urgent search for treating HIV.

  • Antiretroviral Treatment for Adult HIV Infection in 2002: Updated Recommendations of the International AIDS Society-USA Panel. Yeni, Patrick G.; Hammer, Scott M.; Carpenter, Charles C. J.; Cooper, David A.; Fischl, Margaret A.; Gatell, Jose M.; Gazzard, Brian G.; Hirsch, Martin S.; Jacobsen, Donna M.; Katzenstein, David A.; Montaner, Julio S. G.; Richman, Douglas D.; Saag, Michael S.; Schechter, Mauro; Schooley, Robert T.; Thompson, Melanie A.; Vella, Stefano; Volberding, Paul A. // JAMA: Journal of the American Medical Association;7/10/2002, Vol. 288 Issue 2, p222 

    Objective: New information warrants updated recommendations for the 4 central issues in antiretroviral therapy: when to start, what drugs to start with, when to change, and what to change to. These updated recommendations are intended to guide practicing physicians actively involved in human...

  • Factors Associated with Poor Immunologic Responses Despite Viral Suppression in Markedly Immunosuppressed Patients. Collazos, Julio; Asensi, Víctor; Cartón, José Antonio // AIDS Patient Care & STDs;Jun2007, Vol. 21 Issue 6, p378 

    To determine the factors associated with poor immunologic responses despite viral suppression in markedly immunocompromised patients (≤200 CD4 cells per microliter at baseline), individuals with less than 100 CD4 increases after 12 months of nelfinavir-based highly active antiretroviral...

  • Experimental Drugs: The Personal Dimension. Helquist, Michael // Advocate;8/30/88, Issue 506, p40 

    Reports on experimental drugs for AIDS and HIV infections, as discussed by William Woods in the May 1988 issue of 'Focus: A Guide to AIDS Research.' Offer of guidelines to help counselors and their clients discuss whether to take experimental drugs; Contact information.

  • HIV/AIDS Salvage Therapy. Kuritzkes, Daniel R. // AIDS Patient Care & STDs;Apr2003, Vol. 17 Issue 4, p141 

    Interviews Daniel R. Kuritzkes, Associate Professor of Medicine at Harvard Medical School in Boston, Massachusetts and director of AIDS Research, regarding HIV and AIDS salvage therapy. Definition of the term 'salvage therapy'; Method for recognizing treatment failure in patients; Drugs...

  • ANTI-HIV POTENTIAL OF MEDICINALLY IMPORTANT PLANTS. KAUR, RAJANDEEP; KHARB, RAJEEV // International Journal of Pharma & Bio Sciences;Jul-Sep2011, Vol. 2 Issue 3, pP.387 

    The acquired immunodeficiency syndrome (AIDS) is a result of human immunodeficiency virus (HIV) infection which leads to severe suppression of immune functions. AIDS is a real threat to the health of mankind, and the search for effective therapies is still of great importance. However besides...

  • New hope for eradication of HIV from the body: the role of polymeric nanomedicines in HIV/AIDS pharmacotherapy. Lenjisa, Jimma Likisa; Alebachew Woldu, Minyahil; Satessa, Gizaw Dabessa // Journal of Nanobiotechnology;2014, Vol. 12 Issue 1, p1 

    Human immunodeficiency virus continued to be the greatest challenge and killer disease of the 21st century despite the advent of potent highly active antiretroviral therapy which are limited by their severe adverse effects, significant drug interactions, frequent dosing, limited bioavailability,...

  • Time to Virological Failure of 3 Classes of Antiretrovirals after Initiation of Highly Active Antiretroviral Therapy: Results from the EuroSIDA Study Group. Mocroft, A.; Ledergerber, B.; Viard, J. P.; Staszewski, S.; Murphy, M.; Chiesi, A.; Horban, A.; Hansen, A.-B. E.; Phillips, A. N.; Lundgren, J. D. // Journal of Infectious Diseases;12/1/2004, Vol. 190 Issue 11, p1947 

    Objective. The purpose of the present study was to determine the prevalence and incidence of virological triple drug-class failure (TCF) and to summarize the clinical outcome for patients who started receiving highly active antiretroviral therapy (HAART). Methods. The present study is an...

  • World AIDS Day brings hope to those living with HIV/AIDS.  // Gay & Lesbian Times;11/25/2004, Issue 883, p12 

    Editorial. States that the World AIDS Day on December 1, 2004 will bring hope to people living with AIDS and HIV. AIDS Day's representation of progress in the treatment of AIDS, such as the development of AZT and combination drug therapy; Development of novel protease inhibitors that cause fewer...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics